ATIM-24. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Glioblastoma creates an immunosuppressive environment that allows tumor growth. Myeloid derived suppressor cells (MDSCs), a class of immunosuppressive cells, mediate immunosuppression in GBMs. MDSCs are up-regulated in the blood of GBM patients. We have developed a novel strategy to targ...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Peereboom, David M, Vogelbaum, Michael, Mohammadi, Alireza, Alban, Tyler, Brewer, Cathy, Ahluwalia, Manmeet, Sinyuk, Maksim, Lathia, Justin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692853/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.119
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg